Pleasure to share our Outlook on Growth of the US biosimilars market – Key trends and opportunities.

Historically, the US biosimilars market has posed several challenges restricting its penetration. Ambiguous regulatory guidelines contributing to high cost and timelines for development, patent dance causing uncertainties with launch timelines and barriers posed by the innovators limiting the market penetration – all of these led to the biosimilars market only dominated by the innovator companies.

However, over the last 3-5 years, the landscape has evolved favoring biosimilars. The regulatory guidelines have standardized reducing the time and cost of development to at least half. Twenty-five biosimilar products for 6 innovator molecules have contributed to revenues of ~$7B. Biosimilars have captured a 50%+ market share for several molecules. Generic players such as Biocon/Viatris, Teva and Sandoz have witnessed significant growth in their biosimilars revenues.

Over the next 5 years, additional innovator biologics worth ~$35B are expected to face biosimilar competition. With innovators like Pfizer, Boehringer Ingelheim and Coherus exiting the biosimilars space, the generic and specialty biosimilars companies, with established foundation, now have a huge opportunity to capitalize in this oligopolistic market.

The attached presentation provides a detailed analysis of the evolution of the US biosimilars market.

You can download the presentation here.